De novo epigenetic changes at histone and DNA level that affect gene transcription in cancer may be less random than we originally thought. Leukemia fusion proteins associated with specific chromosome translocations could mechanistically determine the epigenetic fate of specific target genes critical for normal hematopoiesis. This seems to be the case with AML1-MTG16, a fusion protein resulting from the t(16;21) translocation, a hallmark of therapy-related leukemia and myelodysplastic syndrome. Here we show that AML1-MTG16 blocks both myeloid differentiation and proliferation in the 32D/WT1-mouse myeloid cell line. These biological effects can be traced to the AML1 and MTG16 moieties of the fusion protein, respectively. Further, we show that AML1-MTG16 can induce epigenetic repressive changes at the histone and DNA level of the AML1 target gene Csf1r (c-fms), encoding the macrophage colony stimulating factor receptor. We observed that, concomitant with Csf1r downregulation, 32D/WT1 cells lost the ability to undergo myeloid differentiation in response to the granulocyte macrophage colony-stimulating factor (GM-CSF). Thus, there seems to be an association between AML1-MTG16-induced myeloid maturation block and epigenetic changes of a myeloid master gene.

, , ,
doi.org/10.1038/sj.onc.1208651, hdl.handle.net/1765/74222
Oncogene: including Oncogene Reviews
Department of Clinical Genetics

Rossetti, S., van Unen, L., Touw, I., Hoogeveen, A., & Sacchi, N. (2005). Myeloid maturation block by AML1-MTG16 is associated with Csf1r epigenetic downregulation. Oncogene: including Oncogene Reviews, 24(34), 5325–5332. doi:10.1038/sj.onc.1208651